A combination therapy with PFKFB3 inhibitor and VEGF inhibitor, bevacizumab, improved tumor vasculature, alleviated tumor hypoxia, normalized lactate production, and improved the efficacy and delivery of doxorubicin in glioblastoma [110]. This evidence concerns the gene PFKFB3 and neoplasm.